ReviewBreast cancer research and treatment1995
The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression.
Review in Breast cancer research and treatment, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 103 citations in OpenAlex.
- Secretory defects in pediatric osteosarcoma result from downregulation of selective COPII coatomer proteins.iScience · 2022Article
- Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment.Journal of Cancer · 2020Review
- Antiangiogenic mechanisms and factors in breast cancer treatment.Journal of carcinogenesis · 2016Review
- Chemopreventive apigenin controls UVB-induced cutaneous proliferation and angiogenesis through HuR and thrombospondin-1.Oncotarget · 2014Article
- Potential prognostic, diagnostic and therapeutic markers for human gastric cancer.World journal of gastroenterology · 2014Review
- The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression.Oncogene · 2013Article
- Induction of thrombospondin-1 partially mediates the anti-angiogenic activity of dexrazoxane.British journal of cancer · 2009Article
- Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis.The American journal of pathology · 2008Article
- Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.Journal of mammary gland biology and neoplasia · 2008Review
- Mathematical modeling of tumor-induced angiogenesis.Journal of mathematical biology · 2004Review
- Article
- Angiogenesis, thrombospondin, and ductal carcinoma in situ of the breast.Journal of clinical pathology · 2002Review
- Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice.The American journal of pathology · 2001Article
- A novel in vitro model of tumor angiogenesis.In vitro cellular & developmental biology. Animal · 2000Article
- Review
- Thrombospondin is sequentially expressed and then de-expressed during early pregnancy in the rat uterus.The Histochemical journal · 1999Article
- Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis.The American journal of pathology · 1997Article
- Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.The American journal of pathology · 1996Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Fifteen different natural inhibitors of angiogenesis have now been identified that are produced by mammalian cells and are able to block in vivo neovascularization. The majority of these are able to inhibit endothelial cell activities in vitro and all those tested have demonstrated significant antitumor activity. Most normal cells produce inhibitors of neovascularization that must be downregulated before the cells can develop into angiogenic, malignant tumors. In several cases the production of inhibitors ceases when tumor suppressor genes are inactivated. In the BT549 human breast carcinoma cell line, the reintroduction of a wild type p53 tumor suppressor gene resulted in the stimulation of the secretion of an inhibitor of angiogenesis, thrombospondin-1, and as a result the cells lost their angiogenic phenotype and became able to suppress angiogenesis induced by the parental tumor line. These results provide a new example of tumor suppressor gene control of a natural inhibitor of angiogenesis and add support to the concept that thrombospondin loss may play an important role in the development of some human breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.